MedTrace Logo

Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19

NCT04604678 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-10-04

No results posted yet for this study

Summary

Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.

Conditions

  • Covid19

Interventions

DRUG

Metformin

Metformin at 1500 mg/day

DRUG

Naltrexone

Naltrexone at 4.5 mg/day (LDN)

Sponsors & Collaborators

  • AgelessRx

    lead INDUSTRY

Principal Investigators

  • Sajad Zalzala, MD · AgelessRx

  • Sajad Zalzala, MD · AgelessRx

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-28
Primary Completion
2021-08-31
Completion
2021-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04604678 on ClinicalTrials.gov